{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T04:15:11Z","timestamp":1745122511150,"version":"3.40.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Cytopathology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jasc.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:45:08Z","timestamp":1736149508000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of HER2-Low breast carcinoma in metastatic settings: a cytological approach to proliferation and survival"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6820-5094","authenticated-orcid":false,"given":"Alaa S.","family":"Hrizat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4081-1807","authenticated-orcid":false,"given":"Kelly A.","family":"Doxzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4001-4975","authenticated-orcid":false,"given":"Robert P.","family":"Post","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena F.","family":"Brachtel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jasc.2025.01.001_bib1","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jasc.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jasc.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jasc.2025.01.001_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10549-020-05935-5","article-title":"Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer","volume":"185","author":"Van Raemdonck","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jasc.2025.01.001_bib5","article-title":"Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance","volume":"13","author":"Hu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jasc.2025.01.001_bib6","article-title":"Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach","volume":"26","author":"Turner","year":"2021","journal-title":"Human Pathol Rep"},{"key":"10.1016\/j.jasc.2025.01.001_bib7","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2025.01.001_bib8","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.3390\/cancers13112824","article-title":"HER2-Low Breast Cancer: Molecular Characteristics and Prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jasc.2025.01.001_bib9","doi-asserted-by":"crossref","first-page":"HER2-04","DOI":"10.1158\/1538-7445.SABCS22-HER2-04","article-title":"Abstract HER2-04: HER2-04 Prevalence of HER2-low among Metastatic Breast Cancer Patients and Their Outcomes Compared to HER2 IHC 0","volume":"83","author":"Raghavendra","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jasc.2025.01.001_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1159\/000527391","article-title":"HER2-Low Breast Cancer: Where Are We?","volume":"17","author":"Molinelli","year":"2022","journal-title":"Breast Care"},{"key":"10.1016\/j.jasc.2025.01.001_bib11","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/2159-8290.CD-22-0703","article-title":"Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons","volume":"12","author":"Tarantino","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jasc.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jjco\/hys187","article-title":"Discordant HER2 status between primary breast carcinoma and recurrent\/metastatic tumors using fluorescence in situ hybridization on cytological samples","volume":"43","author":"Arihiro","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jasc.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10549-011-1610-3","article-title":"ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer","volume":"132","author":"Jensen","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jasc.2025.01.001_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41416-023-02287-x","article-title":"Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers","volume":"129","author":"Bergeron","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jasc.2025.01.001_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jasc.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.prp.2016.09.014","article-title":"Utility of cytopathological specimens and an automated image analysis for the evaluation of HER2 status and intratumor heterogeneity in breast carcinoma","volume":"212","author":"Arihiro","year":"2016","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jasc.2025.01.001_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s12282-015-0664-1","article-title":"Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections","volume":"23","author":"Nishimura","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jasc.2025.01.001_bib18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","article-title":"Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort","volume":"159","author":"Karakas","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2025.01.001_bib19","first-page":"605","article-title":"HER2-Low Breast Cancer: Current Landscape and Future Prospects","volume":"15","author":"Shirman","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.jasc.2025.01.001_bib20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/jcp.2004.024224","article-title":"Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma","volume":"58","author":"Sartelet","year":"2005","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jasc.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jasc.2017.09.003","article-title":"HER2 FISH concordance in breast cancer patients with both cytology and surgical pathology specimens","volume":"7","author":"Doxtader","year":"2018","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2025.01.001_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1309\/X8UP920UF4XM1C5C","article-title":"HER-2\/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis","volume":"122","author":"Beatty","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2025.01.001_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.971","article-title":"Evaluating HER2 amplification and overexpression in breast cancer","volume":"195","author":"Bartlett","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.jasc.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jasc.2025.01.001_bib25","article-title":"Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jasc.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-013-2711-y","article-title":"Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome","volume":"141","author":"Lobbezoo","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jasc.2025.01.001_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006308619659","article-title":"Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis","volume":"59","author":"Solomayer","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jasc.2025.01.001_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317705082","article-title":"The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis","volume":"39","author":"Wu","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jasc.2025.01.001_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10585-016-9824-8","article-title":"Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study","volume":"34","author":"Ording","year":"2017","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jasc.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.breast.2008.02.002","article-title":"Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients","volume":"17","author":"Stuart-Harris","year":"2008","journal-title":"Breast"},{"key":"10.1016\/j.jasc.2025.01.001_bib32","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","article-title":"Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients","volume":"96","author":"de Azambuja","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jasc.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2025.01.001_bib34","first-page":"2361","article-title":"Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis","volume":"24","author":"Li","year":"2019","journal-title":"J buon"},{"key":"10.1016\/j.jasc.2025.01.001_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clbc.2015.01.005","article-title":"Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer","volume":"15","author":"S\u00e1nchez-Mu\u00f1oz","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jasc.2025.01.001_bib36","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/cncy.22630","article-title":"Ki-67 index assessment on FNA specimens of gastrointestinal stromal tumor: Correlation with mitotic rate and potential predictive value for risk stratification","volume":"130","author":"Wang","year":"2022","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2025.01.001_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12022-016-9455-2","article-title":"Reliability of Ki-67 Determination in FNA Samples for Grading Pancreatic Neuroendocrine Tumors","volume":"27","author":"D\u00edaz Del Arco","year":"2016","journal-title":"Endocr Pathol"}],"container-title":["Journal of the American Society of Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294525000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294525000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T15:34:27Z","timestamp":1745076867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213294525000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2213294525000018"],"URL":"https:\/\/doi.org\/10.1016\/j.jasc.2025.01.001","relation":{},"ISSN":["2213-2945"],"issn-type":[{"type":"print","value":"2213-2945"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of HER2-Low breast carcinoma in metastatic settings: a cytological approach to proliferation and survival","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Cytopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jasc.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Cytopathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}